Trends in Hepatitis C Virus Infection Therapy: Protease Inhibitors a Step Forward in the Era of Direct Acting Antivirals

Size: px
Start display at page:

Download "Trends in Hepatitis C Virus Infection Therapy: Protease Inhibitors a Step Forward in the Era of Direct Acting Antivirals"

Transcription

1 Trends in Hepatitis C Virus Infection Therapy: Protease Inhibitors a Step Forward in the Era of Direct Acting Antivirals CRISTINA POPESCU 1, 2, SMARANDA GLIGA 1, VICTORIA ARAMĂ 1, 2 1 Matei Bals National Institute of Infectious Diseases, Bucharest, Romania 2 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania The standard of care for the treatment of HCV infected patients was until 11 the association peginterferon-ribavirin with a sustained virologic response of 5%. In 11 another class of antivirals was approved by the FDA and EMEA the HCV-NS3 protease inhibitors. Two molecules are now available: boceprevir and telaprevir. The protease inhibitors are used in association with peginterferon and ribavirin, which remain vital therapy components. Protease inhibitor regimens substantially increased the rate in naïve patients and also in previously relapse patients. Because of the high risk of emerging resistance to protease inhibitors, prior null responders are not yet suitable candidates for triple therapy, the rate in these patients is still very low. Keywords: protease inhibitor, HCV, treatment, sustained virologic response. A. INTRODUCTION B. BACKGROUND Chronic HCVinfection is an important public health problem, affecting more than million people globally (approximately 3% of the global population), patients infected being at risk for progression to cirrhosis (3%) and hepatocellular carcinoma (5%) [1]. What is vital to know is that HCV infection can be cured, the cure rate depending also on the accuracy of antiviral treatment administration. Recent years have signalled a real effervescence regarding introduction of new antiviral drugs, especially the ones with direct antiviral action (DAA direct acting antiviral). Because the response rate to the current standard of care is around 5% [2], two important problems need solving in the near future: improving treatment response for naïve patients and finding new therapeutic solutions for previously treated patients, with therapy failure. The introduction of protease inhibitors represents a major step in managing patients infected with HCV genotype 1, widely accepted as the most frequently involved and difficult to treat viral genotype [3]. The major purpose of antiviral therapy in HCV infected patients is obtaining Sustained Virologic Response (), i.e. demonstrating undetectable HCV viral load, 6 months after completion of therapy. Treatment of HCV infection has consistently improved since The rate has continually increased through permanent changes made to the STANDARD of CARE (SoC). Thus, from the introduction of standard interferon monotherapy with a duration of 6 months and an of 6%, therapy has changed permanently in order to increase the cure rate. Ribaviarin was the first milestone along the road, which caused an additional 3%. A second milestone was pegylated interferon with improved pharmacokinetic and pharmacodynamic qualities, adding 25% of versus standard interferon [4]. Increasing the rate of to 75 % by adding IP to SoC is clearly a step forward in the fight against HCV (Fig. 1). In addition, a better knowledge of the adverse effects of antiviral drugs in adjunction to supportive medication (erythropoietin) determines a lower rate of therapeutic discontinuation and obviously improves the rate. ROM. J. INTERN. MED., 12, 5, 2,

2 118 Cristina Popescu et al. 2 PEG-RBV-PI PEG-RBV 12 m 54 PEG 12 m 39 IFN-RBV 12 m IFN-RBV 6 m IFN 12 m 16 IFN 6 m Fig. 1. History of HCV treatment. C. USE OF PROTEASE INHIBITORS IN CHRONICALLY HCV INFECTED PATIENTS Improved knowledge of the HCV life cycle, its complex structure, led to the discovery of new compounds, so-called Directly acting antiviral agents (DAA). Among the many molecules that are currently under evaluation, two molecules belonging to the IP class receive extensive studies including Phase III trials, and were recently introduced in international treatment guidelines, for both naïve and previously treated patients in therapy failure. We are talking about boceprevir (approved for use in May 11 in the and July 11 in the EU) and telaprevir (approved for use in May 11 in the and September 11 in the EU). We cannot predict when the rest of the molecules under study will be used in the treatment of HCV infection. If we were to consider what happens overall to HCV chronically infected patients following the current SoC, we could say that: 5% register 25% are relapsers % are non-responders 5% register breakthrough (Fig. 2). Because only half of HCV chronically infected patients have a favorable response to the current regimen, the need for new molecules that can improve rates is self-evident. RESPONSE RATE 1 patients 5 patients RVS 5 patients non-rvs 99% undetectable at 5 years 25 relapse 5 breakthrough null responders Failure Require re-treatment Fig. 2. The virologic response after PEG-RBV.

3 3 Trends in Hepatitis C Virus Infection Therapy 119 C.1. USING PI IN NAIVE PATIENTS a. Using boceprevir in naive patients Boceprevir is the first PI introduced in the treatment of HCV infection. The efficacy of boceprevir in treating naïve patients was demonstrated by clinical trials: SPRINT 1 [5] (Phase 2) and SPRINT 2 [6] (Phase III) that led to the approval of its marketing. The SPRINT I study followed the safety, tolerability and antiviral effectiveness of boceprevir in combination with peg interferon and ribavirin and included 5 naïve patients who were randomly assigned in one of the 5 groups: peginterferonribavirin for 48 weeks (PR48w), boceprevirpeginterferon-ribavirin for 24 weeks (BPR24w), boceprevir-peginterferon-ribavirin for 48 weeks (BPR48w), 4 weeks lead-in with peginterferonribavirin then boceprevir-peginterferon-ribavirin for 24 weeks (PR4w/BPR24w) and 4 weeks lead-in with peginterferon-ribavirin then boceprevir-peginterferon-ribavirin for 44weeks (PR4w/BPR44w). Figure 3 shows the rates, according to the treatment regimens that were used. The best rate was achieved with lead-in regimen followed by triple therapy for 44 weeks. The addition of boceprevir to PR is associated with an improved of 37% PR48 BPR 24 BPR48 PR4/BPR24 PR4/BPR44 Fig. 3. The effectiveness of triple therapy using boceprevir, with different regimens. In the phase III SPRINT 2 study 197 naïve patients were included, subsequently randomised in three arms, after a lead- in period of 4 weeks with PR: the first arm with PR and placebo; the second arm used response guide therapy with BPR for 24 weeks, then PR for another weeks and the third arm with 44 weeks of BPR. rates were 38% for arm 1, 63% for arm 2 and 66% for arm 3. Both SPRINT studies demonstrated an additional rate of at least 25%. b. Using telaprevir in naive patients PROVE 1 [7] and PROVE 2 [8] studies evaluated telaprevir- peg interferon- ribavirin (TPR) triple therapy regimens in patients infected with genotype 1 virus. PROVE 1 included 233 patients randomized in one of the three arms. Patients who had received peg interferon- ribavirin (PR) placebo for 48 weeks were included in the control group. Patients who received telaprevir were divided as follows: 12 wks telaprevir + 12 wks PR 12 wks telaprevir + 24 wks PR 12 wks telaprevir + 48 wks PR The rates are presented in Fig. 4. The highest rate was obtained with the 12 week triple therapy regimen followed by 36 weeks of PR. PROVE 2 study enrolled 334 naïve patients, who received various regimens containing telaprevir. The results were similar to the PROVE 1 study. The regimen with the highest was the 12 week telaprevir- peginterferon-ribavirin, followed by 36 weeks of peg interferon- ribavirin. Both PROVE 1 and PROVE 2 studies have shown that shortening the duration of antiviral treatment with peg interferon-ribavirin lowers the rate. In addition, these studies emphasized the role of ribavirin in reducing the risk of relapse and breakthrough.

4 1 Cristina Popescu et al PEG-RBV-placebo 12T12PR 12T24PR 12T48PR Fig. 4. The effectiveness of different triple therapy regimens with telaprevir. The Phase 3 ADVANCE [9] study enrolled 188 patients who were divided into three arms: arm 1 with PR and placebo for 48 weeks (PR48w), arm 2 8 weeks triple therapy followed by response guided duration of PR (T8PR) and arm 3 12 weeks triple therapy, followed by response guided duration of PR (T12PR). Patients with undetectable viral loads at 4 and 12 weeks, received only 24 weeks of treatment. Those with positive viral loads at 4 weeks received 48 weeks of treatment. The best rate was achieved for patients who received 12 weeks of telaprevir (75% vs. 69% if telaprevir was given for 8 weeks) (Fig. 5). These three studies were the basis for the approval of telaprevir marketing. In 11 the results of the ILLUMINATE [1] study were published. This study included 5 naïve patients who received 12 weeks of TPR followed by response guided therapy with PR. The patients with extended rapid virologic response (E-RVR undetectable viral load at weeks 4 and 12 of TPR) were randomly assigned in one of the two groups: T12PR24 and T12PR48. All the patients without received 48 weeks of PR. The rates for the patients with E-RVR were 92% for T12PR24 arm and 88% for T12 PR48 arm, establishing noninferiority of short treatment for the patients with E-RVR PR48 T8PR T12PR Fig. 5. The effectiveness of triple therapy regimens with telaprevir and response guided therapy PR. C.2. USING PIS IN EXPERIENCED PATIENTS About half the patients treated with PEG- RBV fail to achieve. These patients require re-treatment with new molecules that improve the response rate. Patients who have failed previous therapies can be grouped into: Relapser patient with undetectable viral load (VL) at end of treatment but detectable VL after 6 months of follow-up Partial virologic response reduction of VL with at least 2log1 after 12 weeks of treatment, but not undetectable VL Null- responders reduction of VL with less than 2log1 after 12 weeks of treatment.

5 5 Trends in Hepatitis C Virus Infection Therapy 121 a. Using boceprevir in previously treated patients The RESPOND-2 (11) study enrolled 3 experienced patients in therapeutic failure, prior relapsers or partial responders. They were divided into three branches: 4 wks PR (lead-in), then PR-placebo 44 wks 4 wks PR (lead-in), then PR-BOC 32 wks 4 wks PR (lead-in), then PR-BOC 44 wks The best rate, of more than 65%, was achieved with 48 weeks of PEG-RBV and 44 weeks of boceprevir. Compared to the control group, treated with PEG-RBV with an rate of 21%, it is estimated that the association of boceprevir increases the rate to 66%. For relapsers there is a 29% to 75% increase in the (Fig. 6) and for partial response patients an increase from 7 to 52% (Fig. 7). It can be appreciated that for relapsers the combination of PIs has become imperative, while for partial response patients further studies are needed in order to decide whether the association of a PI is sufficient. Unfortunately, the risk of developing resistance to a PI is very high, therefore it has been decided that for nonresponders with a low degree of fibrosis (F1-F2) therapy should be postponed until the release of new molecules that could improve the response rate. PI resistance develops in half the patients, compromising future regimens that contain new molecules (nucleoside or non-nucleoside NS5B polymerase inhibitors, NS5A inhibitors) and need the association of a PI. Triple therapy can be used for patients with a high degree of fibrosis (F3, F4), at risk for progression to HCC PR 48 PR36B32 PR48B44 Fig. 6. The rates using boceprevir for previous relapse or partial responder patients. 46% increase in Fig. 7. Improving rates in relapsers.

6 122 Cristina Popescu et al. 6 b. Using telaprevir in previously treated patients The PROVE 3 study [12] enrolled 453 previously treated patients (relapsers, non-responders, breakthrough). The rates analysis for various regimens is presented in Fig. 8. If we look separately at rates for triple and bitherapy, for relapsers and non-responders, we can conclude: 1. The rate for relapsers increases from %, in the case of bitherapy to 69% for triple therapy, an addition of 49% (2.7 times higher) 2. The rate for non-responders increases from 9 to 39% by adding telaprevir to the bitherapy. As a follow-up to the ADVANCE study, the REALIZE Phase III study enrolled 663 previously treated patients, divided into 3 arms: T12/PR48, lead-in PR4 + 12T/PR 44 and PR48 (Fig. 9). The rates were: 64%, 66% and 17%, respectively. Therefore, the currently agreed regimen for triple therapy is 12 weeks of telaprevir and PEG-RBV, followed by 36 weeks of PEG-RBV. Analyzing patient categories: relapsers, partial responders and null responders showed: for relapsers rates of 24% for PEG- RBV, compared to 83% and 88% for the two regimens containing telaprevir (Fig. 1) for partial responders rates of 15% with SoC, 59% and 54% with triple therapy (Fig. 11) for null responders rates of 5% and 29% with SoC and 33% with triple therapy (Fig. 12). As with boceprevir- based regimens, using telaprevir in null- responders increases the risk of resistance to PIs, which will compromise future DAA regimens. 45% increase in Fig. 8. Improving rates for partial response patients relapser non-responder breakthrough T12PR24 T24PR48 T24P24 PR48 Fig. 9. rates for various telaprevir regimens.

7 7 Trends in Hepatitis C Virus Infection Therapy Increasing with 64% bitherapy triple therapy Fig. 1. Improving rates for relapsers Increasing with 39 % bitherapy triple therapy Fig. 11. Improving rates for partial responders bitherapy triple therapy Increasing with 24% Fig. 12. Improving rates for null responders. D. PI BASED REGIMENS APPROVED BY INTERNATIONAL GUIDELINES In late 11, the American Association for the Study of Liver Diseases (AASLD) amended therapeutic guidelines for HCV infected patients, introducing boceprevir and telaprevir in both naive and previously treated patients [14]. The same changes were published in early 12 in the UK [15]. D.1. BOCEPREVIR- BASED REGIMEN Boceprevir therapy is always associated with PEG-RBV, after 4 weeks of lead-in. The total duration of treatment is presented in Table I.

8 124 Cristina Popescu et al. 8 D.2. TELAPREVIR- BASED REGIMEN Telaprevir based regimens are always associated with PEG-RBV. Telaprevir and PEG-RBV are initiated simultaneously and continued for 12 weeks. The duration of the subsequent PEG-RBV treatment is presented in Table II. E. IMPROVING RATES WITH PROTEASE INHIBITORS Numerous studies using protease inhibitors have been published recently. New molecules are being studied, besides the already approved boceprevir and telaprevir. Table III shows some of the recently conducted studies, that used PIs in naive and previously treated patients. F. ADVERSE EFFECTS OF PROTEASE INHIBITORS The main adverse effects of boceprevir and telaprevir are presented in Table IV. We only listed the adverse events reported for regimens subsequently included in the current guidelines. The main side-effects associated with boceprevir are: dysgeusia (which does not require changes in treatment regimen), anaemia and neutropenia. Telaprevir has slightly different side- effects, with an increase in skin rash and anorectal symptoms. The rash leads to discontinuation of telaprevir in 5 7% of cases. The rash could be eczematous and pruritic, and in about 5% of cases appears in the first month of treatment. The anorectal symptoms are rarely a cause of discontinuation. Because of the risk of resistance, dose reduction for boceprevir and telaprevir should not be used. Table I Therapeutic algorithm for boceprevir- based regimens HCV RNA Duration of therapy S8 S24 Naive patients undetectable undetectable 4 wks lead-in PEG-RBV + 24 wks triple therapy detectable undetectable 4 wks lead-in PEG-RBV + 32 wks triple therapy + 12 wks PEG-RBV Naive patients, without risk factors for poor outcome;viral load after lead-in. If viral load is undetectable, the patient will receive biotherapy. Naive patients, with cirrhosis, 44 wks of triple therapy. Naive patients, with cirrhosis,viral load at 4 wks has not decreased by at least 1 log, discontinuation of therapy to prevent risk of resistance. Therapy failure (nonresponder undetectable undetectable 4 wks lead-in PEG-RBV + and relapser) detectable undetectable 32 wks triple therapy + 12 wks PEG-RBV Patients with cirrhosis and null-responders, treated with 44 wks of triple therapy. Patients with cirrhosis and null-repsponders, viral load after lead-in has not decreased by at least 1 log, discontinuation of therapy to prevent risk of resistance. If viral load> 1 UI/ml at S 12, stop therapy Detectable viral load at S24, stop therapy Boceprevir dose is mg x 3/day Table II Therapeutic algorithm for telaprevir- based regimens HCV-RNA Duration of therapy S4 S12 Naive patients and relapsers undetectable undetectable 12 wks triple therapy + 12 wks PEG-RBV detectable detectable/undetectable 12 wks triple therapy + 36 wks PEG-RBV R Partial and null responders Undetectable or <1 Undetectable or <1 UI/ml 12 wks triple therapy + UI/ml 36 wks PEG-RBV Patients with cirrhosis, partial and null responders will receive 48 wks of therapy, regardless of EVR. For patients with undetectable VL at S12, but under 1 UI/ml, repeat VL at S24. If positive, regardless of value, stop therapy. VL>1UI/ml at S4 or S12 requires stopping all regimens

9 9 Trends in Hepatitis C Virus Infection Therapy 125 Vierling J (16) NEXT-1 nerlaprevir + PR 12NVR/PR/12PR Table III Studies with Pis based regimens Study Year Sample naïve patients relapsers nonresponders % Okanoue T, (17) Telaprevir+PR 12T/24PR Nelson D.R (18) ZENITH study telaprevir +PR 12VX-222/T/PR Gordon S.C (19) Boceprevir+PR 4PR/24BPR/PR Larrey DG() Danoprevir+PR 2DNPPR/46PR Ogert R.A (21) (NEXT-2, RESPOND-2) Boceprevir + PR Vierling JM (22) PROVIDE study Boceprevir + PR 4PR/44BPR McCone J (23) Treatmentnaive black patients from SPRINT-2 Boceprevir + PR 4PR/44BPR Mann M (24) Vaniprevir (MK-79) + PR 4MK-79PR44PR 11 Japan (197 naïve, 3 trtfailure) 1 France Germany %.6% (% cumulative RBV) % 83% (from 197 patients) % 15 (197 naïve) 66% G1b 53% G1a 88.1%, 92.8% (% cumulative RBV) 78% (from 3 patients) 73% G1b 64% G1a 34.4% 45.5% (% cumulative RBV) 46 41% AT EOT.svr not available yet % % Table IV The main adverse effects Boceprevir(6,11) SPRINT 2/RESPOND 2 (response guided therapy) Telaprevir (9, 1, 13) ADVANCE, REALISE, ILLUMINATE (T12PR) Serious adverse events 1 11% 9 12% Discontinuation due to adverse events 8 12% 1 18% Anorectal symptoms NR 8 15% Dysgeusia 37 43% 12% Anaemia 43 49% 3 39% Neutropenia 19 24% 14% Rash 17 25% 37% Fatigue 53 55% 55 68% Pruritus 18 24% 5 52% Nausea 43 48% 35 47% Diarrhoea 22 23% 25 3% Anaemia during PI treatment The use of PIs is associated with a 25% increase in the rate of anaemia. Only 3 7% of the patients who developed anaemia during PI treatment registered severe anaemia (grade 3 or 4 haemoglobin level below 8 g/dl). Only 2 3% of the patients discontinued the treatment. In boceprevir studies, anaemia was treated with erythropoietin but in studies using telaprevir, the use of erythropoietin was forbidden. For telaprevir studies, the management of anaemia meant reducing the ribavirin dose, which did not induce a decrease in the rate.

10 126 Cristina Popescu et al. 1 CONCLUSIONS 1. For relapse patients, it is highly advisable to use a protease inhibitor (boceprevir or telaprevir) for the next therapeutic regimen. The association of boceprevir and telaprevir doubles the rate. 2. The rate for non-responders is much lower than the rate for relapsers, with an increased risk of PI resistance. It is therefore recommended, if the fibrosis is not very advanced to postpone therapy until new molecules are approved. 3. Determining the IL28b polymorphism is useful in choosing the right regimen for naive patients. Patients with unfavourable IL28b genotypes are candidates for triple therapy. 4. The rates for naive patients are close to % with the use of protease inhibitors associated to peginterferon-ribavirin. Standardul de aur în tratamentul hepatitei cronice cu VHC a fost până în 11 terapia combinată peginterferon-ribavirină, cu o rată a răspunsului virusologic susţinut () de 5%. În 11 FDA şi EMEA au aprobat o nouă clasă de antivirale inhibitorii de protează HCV-NS3. În prezent, sunt disponibile două molecule: boceprevir şi telaprevir. Inhibitorii de protează sunt utilizaţi în asociere cu peginterferon şi ribavirină, acestea din urmă rămânând în continuare componente vitale ale terapiei antivirale în hepatita cronică cu VHC, care actualmente din biterapie tinde să devină triterapie. Inhibitorii de protează cresc semnificativ rata de la pacienţii naivi, dar şi la relapseri. Din cauza riscului crescut de apariţie a rezistenţei la inhibitorii de protează, null-responderii anteriori nu sunt candidaţi la triplă terapie iar rata de este încă foarte scăzută la aceşti pacienţi. Corresponding author: Prof. Victoria Aramă, Matei Balş National Institute of Infectious Diseases, 1, Calistrat Grozovici, 2115, Bucharest, Romania ralsan@gmail.com REFERENCES 1. LAVANCHY D., The global burden of hepatitis C, Liver Int 9; 29 (Suppl. 1): McHUTCHISON J.G., LAWITZ E.J., SHIFFMAN M.L. et al., Peginterferon alfa-2b or alfa- 2a with ribavirin for treatment of hepatitis C infection, N Engl J Med 9; 361: HADZIYANNIS S.J., SETTE H. Jr., MORGAN T.R. et al., for PEGASYS International Study Group, Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med 4;1: BROK J., GLUUD L.L., GLUUD C., Meta-analysis: Ribavirin Plus Interferon vs. Interferon Monotherapy for Chronic Hepatitic C an Updated Cochrane Review, Alimentary Pharmacology & Therapeutics, 1; 32 (7): KWO P.Y., LAWITZ E.J., MCCONE J. et al., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, Lancet 1; 376: POORDAD F., MCCONE J. Jr., BACON B.R. et al., Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med 11; 364: McHUTCHISON J.G., EVERSON G.T., GORDON S.C. et al., Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection, N Engl J Med 9; 36: HEZODE C., FORESTIER N., DUSHEIKO G. et al., Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 9; 36: JACOBSON I.M., McHUTCHISON J.G.,DUSHEIKO G. et al., Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med 11; 364: SHERMAN K., FLAMMS, AFDHAL N. et al., Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection, N Engl J Med 11, 365, BACON B.R., GORDON S.C., LAWITZ E. et al., Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med 11; 364: McHUTCHISON J.G., MANNS M., MUIR A. et al., Telaprevir for Previously Treated Chronic HCV Infection, N Engl J Med 1, 362, ZEUZEM S., ANDREONE P., POL S. et al., Telaprevir for retreatment of HCV infection, N Engl J Med 11; 364:

11 11 Trends in Hepatitis C Virus Infection Therapy GHANY M.G., NELSON D.R., STRADER D.B. et al., An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 11 Practice Guideline by the American Association for the Study of Liver Diseases, Hepatology 11, RAMACHANDRAN P., FRASER A., AGARWAL K. et al., UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients, Aliment Pharmacol Ther 12; 35: VIERLING J.M. et al., Once daily nerlaprevir (NVR; SCH 9518) and ritonavir (RTV) in Combination with Peginterferon alfa- 2b/Ribavirin (PR) for 12 weeks plus 12 weeks PR in Treatment- Naïve Patients with HCV Genotype-1 (G1): results from NEXT-1, a Phase 2 Study, AASLD, OKANOUE T. et al., Telaprevir in combination with peginterferon alfa 2b and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan, AASLD, NELSON D.R. et al., VX-222/telaprevir in combination with peginterferon- alfa 2a and ribavirin in treatment- naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, 12 interim analysis, AASLD, GORDON S.C. et al., Effect of Baseline Viral load (VL) on response to Boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (PR) in patients infected with HCV genotype 1, AASLD, 11.. LARREY D.G. et al., High sustained virological response () rate for danoprevir for only 14 days associated with peginterferon alpha 2a and ribavirin in treatment chronic HCV genotype 1 patients, AASLD, OGERT R.A., Genotypic and phenotypic correlates of resistance in HCV genotype 1a and 1b infected patients treated with boceprevir plus peginterferon alpha and ribavirin, AASLD, VIERLING J.M. et al., Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE study, AASLD, McCONE J. et al., Treatment-Naïve Black Patients Treated with Boceprevir (BOC) Combined with Peginterferon alfa-2b + Ribavirin (PR): Results from HCV SPRINT-2, AASLD, MANNS M. et al., Sustained Viral Response () Rates in Genotype 1 Treatment-naïve Patients with Chronic Hepatitis C (CHC) Infection Treated with Vaniprevir (MK-79), a NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days, AASLD, 1. Received March 26, 12

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Oral combination therapy: future hepatitis C virus treatment? Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following

More information

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International

More information

Protease inhibitor based triple therapy in treatment experienced patients

Protease inhibitor based triple therapy in treatment experienced patients Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber

More information

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum

More information

Infection with hepatitis C virus (HCV) is a global health concern,

Infection with hepatitis C virus (HCV) is a global health concern, Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor

More information

Antiviral agents in HCV

Antiviral agents in HCV Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million

More information

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago

More information

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD

New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b

More information

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1 ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical

More information

Best of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS

Best of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals

More information

Treatment of chronic hepatitis C virus infection in the near future

Treatment of chronic hepatitis C virus infection in the near future EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the

More information

Hepatitis C Treatment 2014

Hepatitis C Treatment 2014 Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype

More information

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)

More information

Current Standards in the Treatment of Chronic Hepatitis C

Current Standards in the Treatment of Chronic Hepatitis C REVIEW ARTICLE Current Standards in the Treatment of Chronic Hepatitis C Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem SUMMARY Background: In Germany, 0 000 to 500 000 people are chronically infected

More information

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and

More information

New developments in HCV research and their implications for front-line practice

New developments in HCV research and their implications for front-line practice New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013

More information

Hepatitis C Therapy Falk Symposium September 20, 2008

Hepatitis C Therapy Falk Symposium September 20, 2008 Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the

More information

Introduction. The ELECTRON Trial

Introduction. The ELECTRON Trial 63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver

More information

SVR Updates from the 2013 EASL

SVR Updates from the 2013 EASL Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations

More information

ةي : لآا ةرقبلا ةروس

ةي : لآا ةرقبلا ةروس سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

Pharmacological management of viruses in obese patients

Pharmacological management of viruses in obese patients Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician

More information

Triple therapy with telaprevir or boceprevir: management of side effects

Triple therapy with telaprevir or boceprevir: management of side effects Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber

More information

Special Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting

Special Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42

More information

Associate Professor of Medicine University of Chicago

Associate Professor of Medicine University of Chicago Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death

More information

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014

More information

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D. Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,

More information

Many promising small molecule inhibitors directed

Many promising small molecule inhibitors directed GASTROENTEROLOGY 2012;142:1351 1355 Will Interferon-Free Regimens Prevail? Christoph Welsch Stefan Zeuzem Department of Internal Medicine I, J. W. Goethe University Hospital, Frankfurt/Main, Germany Many

More information

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of

More information

Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience

Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy

More information

Optimal Treatment with Boceprevir. Michael Manns

Optimal Treatment with Boceprevir. Michael Manns Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency

More information

Les Inhibiteurs de Protéase du VHC

Les Inhibiteurs de Protéase du VHC Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est

More information

Evolution of Therapy in HCV

Evolution of Therapy in HCV Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR

More information

Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon

Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies Advances in treatment of HCV Dr John F Dillon Disclosure slide I have received consulting fees and Honoraria from MSD, Abbott,

More information

SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano

SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed

More information

Hepatitis C Virus Treatments: Present and Future

Hepatitis C Virus Treatments: Present and Future Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,

More information

Treating HCV Genotype 2 & 3

Treating HCV Genotype 2 & 3 Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy

More information

Clinical Management: Treatment of HCV Mono-infection

Clinical Management: Treatment of HCV Mono-infection Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry

More information

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:

More information

Drug Class Prior Authorization Criteria Hepatitis C

Drug Class Prior Authorization Criteria Hepatitis C Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review

More information

Virological Tools and Monitoring in the DAA Era

Virological Tools and Monitoring in the DAA Era Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital

More information

Estimates suggest that if 1998 treatment practices were

Estimates suggest that if 1998 treatment practices were n repts n A Review of Standard and Newer Treatment Strategies in Hepatitis C Tram T. Tran, MD Abstract Chronic infection with hepatitis C virus (HCV) is common, but underdiagnosed and undertreated wldwide.

More information

TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update

TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update DATE: 02 January 2015 RESEARCH QUESTION What is the

More information

Predictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid

Predictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing

More information

Chronic Hepatitis C Drug Class Monograph

Chronic Hepatitis C Drug Class Monograph Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed

More information

Background: Narlaprevir (SCH )

Background: Narlaprevir (SCH ) Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,

More information

Should Elderly CHC Patients (>70 years old) be Treated?

Should Elderly CHC Patients (>70 years old) be Treated? Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),

More information

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade

More information

Treatments of Genotype 2, 3,and 4: Now and in the future

Treatments of Genotype 2, 3,and 4: Now and in the future Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve

More information

Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors

Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science

More information

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),

More information

Chronic Hepatitis C Drug Class Prior Authorization Protocol

Chronic Hepatitis C Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona

Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use DOI 10.1007/s10620-011-1604-3 ORIGINAL ARTICLE Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use Paul J. Gaglio Noah Moss Camille McGaw John Reinus Received: 15 December 2010

More information

Drug Class Prior Authorization Criteria Hepatitis C

Drug Class Prior Authorization Criteria Hepatitis C Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization

More information

Interferon-based and interferon-free new treatment options

Interferon-based and interferon-free new treatment options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and

More information

Hepatitis C Management and Treatment

Hepatitis C Management and Treatment Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause

More information

Month/Year of Review: November 2011 End date of literature search: 4 th Quarter alone

Month/Year of Review: November 2011 End date of literature search: 4 th Quarter alone Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: November 2011 End date of literature

More information

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir Published 24 February 2012, doi:10.4414/smw.2012.13516 Cite this as: Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir Swiss Association for the Study

More information

Improving Treatment Success Rates for HCV in a Managed Care Setting

Improving Treatment Success Rates for HCV in a Managed Care Setting Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and

More information

Update on the Treatment of HCV

Update on the Treatment of HCV Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure

More information

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C Journal of Viral Hepatitis, 2012, 19, e134 e142 doi:10.1111/j.1365-2893.2011.01528.x Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic

More information

Hepatitis C Prior Authorization Policy

Hepatitis C Prior Authorization Policy Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,

More information

For the RESPOND-2 Investigators

For the RESPOND-2 Investigators HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon

More information

Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C

Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction

More information

Review Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection

Review Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection Antiviral Therapy 211; 16:1187 121 (doi: 1.3851/IMP1934) Review Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection Peter Ferenci 1 *, K Rajender Reddy 2 1 Department

More information

TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona

TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment

More information

Hepatitis C Resistance Associated Variants (RAVs)

Hepatitis C Resistance Associated Variants (RAVs) Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C

More information

Treatment with the New Direct Acting Antivirals for Hepatitis C

Treatment with the New Direct Acting Antivirals for Hepatitis C Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives

More information

WHO Global Hepatitis Program. Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries

WHO Global Hepatitis Program. Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries WHO/HIV/201433 World Health Organization 2014 Global Hepatitis Programme Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries PICO 7: Treatment

More information

Current Treatments for HCV

Current Treatments for HCV Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,

More information

Emerging Approaches for the Treatment of Hepatitis C Virus

Emerging Approaches for the Treatment of Hepatitis C Virus Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and

More information

Interferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives

Interferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives TAJ December 2008; Volume 21 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review Article Interferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives

More information

Saeed Hamid, MD Alex Thompson, MD, PhD

Saeed Hamid, MD Alex Thompson, MD, PhD Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-

More information

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research

More information

Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3

Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany

More information

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor

More information

Current Standard of Care for Naïve HCV Patients (SVR)

Current Standard of Care for Naïve HCV Patients (SVR) Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg

More information

Developments in the Treatment of Hepatitis C: A New Era

Developments in the Treatment of Hepatitis C: A New Era Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for

More information

Emerging Therapies for Hepatitis C

Emerging Therapies for Hepatitis C Gut and Liver, Vol. 8, No. 5, September 2014, pp. 471-479 Review Emerging Therapies for Hepatitis C Do Young Kim, Sang Hoon Ahn, and Kwang-Hyub Han Department of Internal Medicine, Yonsei University College

More information

Changing Direction Towards More Effective HCV Treatment

Changing Direction Towards More Effective HCV Treatment Changing Direction Towards More Effective HCV Treatment By: Prof.Dr.Abdel fattah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine The most common disease in the world HCV infects almost

More information

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany : Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained

More information

New Developments in the Treatment of Hepatitis C Virus Infection from Digestive Disease Week 2011

New Developments in the Treatment of Hepatitis C Virus Infection from Digestive Disease Week 2011 J u n e 2 0 1 1 A S P E C I A L M E E T I N G R E V I E W E D I T I O N V o l u m e 7, I s s u e 6, S u p p l e m e n t 1 0 New Developments in the Treatment of Hepatitis C Virus Infection from Digestive

More information

Why make this statement?

Why make this statement? HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed

More information

Direct acting anti-virals: the near future

Direct acting anti-virals: the near future Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should

More information

Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine

Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio

More information

Direct Acting Antivirals for the Treatment of Hepatitis C Infection

Direct Acting Antivirals for the Treatment of Hepatitis C Infection Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment

More information

HCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD

HCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.

More information

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on

More information